DIVA Laboratories Ltd (4153) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of DIVA Laboratories Ltd TWD 21.82, price TWD 31.60, upside -31.0%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DIVA Laboratories Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays.
Show more
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is headquartered in New Taipei City, Taiwan.
Stock analysis
DIVA Laboratories Ltd (4153) currently trades at 31.60 TWD, while our model-based Fair Value estimate is 21.82 TWD, implying the stock looks roughly 44.8% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 32.65 TWD per share, and 4 of the 24 models we run sit above the 31.60 TWD price.
Bear case: the Growth DCF group reads lowest at 11.54 TWD, and 20 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 16.68 TWD (bear) to 26.94 TWD (bull), the price of 31.60 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
DIVA Laboratories Ltd reported revenue of 869M TWD in FY2025 versus 712M TWD in FY2021, a compound +5.1%/yr. Reported net income was 90.5M TWD in FY2025, compounding +42.7%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 1.9B TWD (≈ $58.2M) · P/E ratio 20.5 · P/S ratio 2.14 · EPS (TTM) 1.54 TWD · Dividend yield 6.3% · Net margin 10.4% · Return on equity 9.5% · Return on assets (EBIT) 7.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −31%, 4153 screens richer than that median.
Fair Value models
Bear 16.68 TWDFair Value 21.82 TWDBull 26.94 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+39.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.9%
Dividend (yield on the price)6.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+41.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +39.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−32% · Below median
Profitability
Return on equity (TTM)10% · Above median
Return on assets5% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth8% · Above median
Dividend yield (TTM)6.3% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)20.5× · Cheaper than median
P/B1.83× · Pricier than median
P/S (TTM)2.13× · Cheaper than median
P/FCF3.0× · Cheaper than median
EV/EBITDA13.1× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)38· sector 25
PAST (return on equity)38· sector 8
HEALTH (low debt)0· sector 95
DIVIDEND (yield)100· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DIVA Laboratories Ltd (4153) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 21.82 TWD versus a price of 31.60 TWD, about −31% upside (overvalued).
What is the fair value of 4153?
Our model-based fair value for DIVA Laboratories Ltd is 21.82 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 31.60 TWD.
What is the quality score of 4153?
DIVA Laboratories Ltd has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DIVA Laboratories Ltd (4153)?
Our model-based price target is the fair value of 21.82 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 16.68 TWD, optimistic scenario 26.94 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the DIVA Laboratories Ltd stock forecast for 2026?
Our models put fair value at 21.82 TWD, about −31% upside versus a price of 31.60 TWD (overvalued). Cautious scenario 16.68 TWD, optimistic scenario 26.94 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of DIVA Laboratories Ltd (4153)?
DIVA Laboratories Ltd reported trailing-twelve-month revenue of about 885M TWD (latest available figure, as of Sep 24, 2026).
Does DIVA Laboratories Ltd pay a dividend?
DIVA Laboratories Ltd currently shows a dividend yield of about 6.33% relative to its recent price (as of Sep 24, 2026).
What growth is priced into DIVA Laboratories Ltd (4153)?
For today's price to be fair in a discounted-cash-flow model, DIVA Laboratories Ltd would have to grow free cash flow by +41.8 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 4153 use?
Our models discount DIVA Laboratories Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.20, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DIVA Laboratories Ltd that is +41.8 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has DIVA Laboratories Ltd (4153) delivered so far?
Over the past 5 years revenue at DIVA Laboratories Ltd grew +3.4 % a year. The price currently implies +41.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DIVA Laboratories Ltd (4153) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into DIVA Laboratories Ltd (+41.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DIVA Laboratories Ltd (4153)?
The free-cash-flow yield on the price is 1.07 %: that much free cash flow DIVA Laboratories Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DIVA Laboratories Ltd (4153)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DIVA Laboratories Ltd it is 21.82 TWD per share (as of Sep 24, 2026), against a price of 31.60 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is DIVA Laboratories Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4153 trades above its calculated fair value: price 31.60 TWD, fair value 21.82 TWD, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4153?
No. The price is what the market pays today (31.60 TWD); the fair value is what the company's own numbers justify (21.82 TWD). For DIVA Laboratories Ltd the two are 9.78 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is DIVA Laboratories Ltd worth?
The market values DIVA Laboratories Ltd at about 1.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 31.60 TWD; our models calculate a fair value of 21.82 TWD per share.
What do the bullish and bearish scenarios say about 4153?
Our models span a range for DIVA Laboratories Ltd: cautious scenario 16.68 TWD, base 21.82 TWD, optimistic 26.94 TWD per share (as of Sep 24, 2026, price 31.60 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4153?
DIVA Laboratories Ltd trades at a price-to-earnings ratio of 20.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 21.82 TWD is built from several models across several years. Other multiples: P/B 1.8, P/S 2.1, EV/EBITDA 13.1.
How solid is the balance sheet of DIVA Laboratories Ltd (4153)?
Balance-sheet figures for DIVA Laboratories Ltd (as of Sep 24, 2026): return on equity 9.5%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 4153 from its 52-week high?
DIVA Laboratories Ltd trades at 31.60 TWD, about 19% below its 52-week high of 38.95 TWD and 6% above the low of 29.69 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 21.82 TWD is for.
Which stocks are comparable to DIVA Laboratories Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DIVA Laboratories Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 31.60 TWD, calculated fair value 21.82 TWD (−31%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4153 calculated?
We run DIVA Laboratories Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 21.82 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. DIVA Laboratories Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DIVA Laboratories Ltd (4153)?
The closing price on Sep 24, 2026 was 31.60 TWD. Our model-based fair value is 21.82 TWD, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DIVA Laboratories Ltd right now?
The price sits above even our optimistic bull case (26.94 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of DIVA Laboratories Ltd
How large is the market capitalisation of DIVA Laboratories Ltd (4153)?
The market capitalisation of DIVA Laboratories Ltd is 1.9B TWD (≈ $58.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DIVA Laboratories Ltd (4153)?
The price-to-sales ratio of DIVA Laboratories Ltd is 2.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DIVA Laboratories Ltd (4153)?
Earnings per share at DIVA Laboratories Ltd are 1.54 TWD (price ÷ EPS = P/E 20.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DIVA Laboratories Ltd (4153)?
The dividend yield of DIVA Laboratories Ltd is 6.3% (payout 130%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DIVA Laboratories Ltd (4153)?
The net margin of DIVA Laboratories Ltd is 10.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DIVA Laboratories Ltd (4153)?
The return on equity (ROE) of DIVA Laboratories Ltd is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DIVA Laboratories Ltd (4153)?
On an EBIT basis the return on assets of DIVA Laboratories Ltd is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DIVA Laboratories Ltd (4153)?
The operating margin of DIVA Laboratories Ltd is 12.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DIVA Laboratories Ltd (4153)?
Revenue at DIVA Laboratories Ltd is growing +7.6% versus a year earlier (3y avg −2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does DIVA Laboratories Ltd (4153) hold?
DIVA Laboratories Ltd holds more cash than debt, 346M TWD net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch DIVA Laboratories Ltd in the live analysis
One click puts DIVA Laboratories Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
